PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32026330-2	2021	DOTA-JR11 is a SST2 targeting ligand with a five times higher tumor uptake than DOTATATE, and holds promise to improve plaque imaging.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	0-4	somatostatin receptor 2	Mus musculus	15-19	
18927338-2	2008	Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst2-ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	20-76	somatostatin receptor 2	Mus musculus	111-116	
18927338-2	2008	Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst2-ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	20-76	somatostatin receptor 2	Mus musculus	188-193	
18927338-2	2008	Additionally, 111In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst2-ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	20-76	somatostatin receptor 2	Mus musculus	188-193